AIRNA raised $60 million in a Series A financing led by Forbion to advance RNA editing medicines and progress its AATD program into clinical trials.
AIRNA raised $60 million in a Series A financing led by Forbion to advance RNA editing medicines and progress its AATD program into clinical trials.
07/31/24, 11:01 AM
Location
cambridgeMoney raised
$60 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Nd Capital, Arch Venture Partners, Alexandria Venture Investments, Ono Venture Investment, Forbion
AIRNA has successfully closed an oversubscribed $60 million Series A financing round, bringing total funding to $90 million. The funds will be utilized to advance their lead product candidate into clinical trials and further develop their pipeline.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.